Bio

Dr. Holden is a board-certified, fellowship-trained medical oncologist. He is a Clinical Assistant Professor at Stanford University School of Medicine.

He specializes in care for people with gastrointestinal cancer including those of the colon, rectum, esophagus, liver, pancreas, and stomach. Dr. Holden works closely with patients to prepare personalized, comprehensive, and compassionate care plans that optimize healing and quality of life.

Dr. Holden has conducted research into a wide range of subjects. He co-developed and established a multi-center trial investigating a new treatment regimen for gastric cancer. He has studied use of a fitness tracker to assess activity levels and toxicities in patients with colorectal cancer. He also has written invited commentary on the rapidly advancing field of genetic testing as well as a review on recent updates on the treatment of early-stage rectal cancer.

He has published his research findings in articles in peer-reviewed journals including JAMA, the Journal of Clinical Oncology, Cortex, and elsewhere. He has made poster presentations to his peers at meetings including the ASCO Gastrointestinal Cancers symposium and House Staff Quality Improvement and Patient Safety Conference, a meeting held annually at Thomas Jefferson University.

Dr. Holden has volunteered his time and expertise to help improve access to health care for homeless and underserved populations.

In his free time, he runs, reads, plays the acoustic guitar, and travels.

Clinical Focus

  • Medical Oncology

Academic Appointments

Professional Education

  • Board Certification: American Board of Internal Medicine, Medical Oncology (2022)
  • Fellowship, Fox Chase Cancer Center, PA (2022)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2019)
  • Residency: Thomas Jefferson University Hospital Internal Medicine Residency (2019) PA
  • Internship: Riverside Methodist Hospital Transitional Year (2016) OH
  • Medical Education: University of Oklahoma College of Medicine (2015) OK

Contact

  • Academic
    tholden@stanford.edu
    University - Academic staff Department: Medicine - Med/Oncology Position: Clinical Assistant Professor
  • Clinical (Primary)  Medical Oncology 875 Blake Wilbur Dr Clinic A MC 6560 Stanford, CA 94305 (650) 723-8748 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5151

Clinical Trials

  • Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients Recruiting

    This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in Patients with metastatic or unresectable gastric adenocarcinoma (including GEJ tumors) that are HER2-overexpressing (IHC 3+ or IHC2+/ISH+). Patients must have progressed or been intolerant of at least one prior line of chemotherapy + HER2 directed therapy.

    View full details

All Publications

  • Nonoperative Management for Rectal Cancer. Cancer journal (Sudbury, Mass.) Pollom, E. L., Sheth, V. R., Dawes, A. J., Holden, T. 2024; 30 (4): 238-244

    Abstract

    The treatment paradigm for rectal cancer has been shifting toward de-escalated approaches to preserve patient quality of life. Historically, the standard treatment in the United States for locally advanced rectal cancer has standardly comprised preoperative chemoradiotherapy coupled with total mesorectal excision. Recent data challenge this "one-size-fits-all" strategy, supporting the possibility of omitting surgery for certain patients who achieve a clinical complete response to neoadjuvant therapy. Consequently, patients and their physicians must navigate diverse neoadjuvant options, often in the context of pursuing organ preservation. Total neoadjuvant therapy, involving the administration of all chemotherapy and radiation before total mesorectal excision, is associated with the highest rates of clinical complete response. However, questions persist regarding the optimal sequencing of radiation and chemotherapy and the choice between short-course and long-course radiation. Additionally, meticulous response assessment and surveillance are critical for selecting patients for nonoperative management without compromising the excellent cure rates associated with trimodality therapy. As nonoperative management becomes increasingly recognized as a standard-of-care treatment option for patients with rectal cancer, ongoing research in patient selection and monitoring as well as patient-reported outcomes is critical to guide personalized rectal cancer management within a patient-centered framework.

    View details for DOI 10.1097/PPO.0000000000000727

    View details for PubMedID 39042774

  • Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX). Pollom, E. L., Fisher, G. A., Shelton, A., Johnson, T., Chen, C., Jackson, S., Shaheen, S., Holden, T., Bien, J., King, D., Morris, A. M., Kin, C., Dawes, A., Kirilcuk, N., Gahagan, J., Vitzthum, L., Sheth, V., Brown, E., Pratapneni, A., Chang, D. LIPPINCOTT WILLIAMS & WILKINS. 2024

    View details for Web of Science ID 001275557400852